MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, SLNCF had -$39,623K decrease in cash & cash equivalents over the period. -$45,039K in free cash flow.

Cash Flow Overview

Change in Cash
-$39,623K
Free Cash flow
-$45,039K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
Net loss
-76,842
Depreciation expense
235
Amortization expense
207
Share-based compensation expense
8,160
Net foreign exchange impacts
-10,792
Other income, net
2,600
Income tax expense
11
Decrease/(increase) in trade receivables
-994
Decrease/(increase) in other current assets
-7,757
Decrease in r&d benefit receivable
-3,851
Decrease in other long-term assets
-3,401
(decrease)/increase in trade and other payables
-502
Decrease in contract liabilities
-302
Decrease in operating lease liabilities
-146
Net cash provided by/(used in) operations
-44,984
Redemption of term deposits
98,036
Purchase of term deposits
92,635
Purchase of property, plant and equipment
55
Net cash provided by/(used in) investing activities
5,346
Proceeds from issue of ordinary shares
15
Net cash provided by financing activities
15
(decrease)/increase in cash and cash equivalents
-39,623
Cash and cash equivalents at beginning of period
121,330
Effect of exchange rate changes on cash
324
Cash and cash equivalents at end of period
82,031
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Silence Therapeutics plc (SLNCF)

Silence Therapeutics plc (SLNCF)